/

Treatment

Inside Ibogaine: The Overlooked Yet Promising Psychedelic for Addiction Recovery

Inside Ibogaine: The Overlooked Yet Promising Psychedelic for Addiction Recovery

,
Ibogaine’s anti-addictive properties are known to work wonders on people struggling with various substances, such as cocaine, amphetamines, alcohol, nicotine and more.
The Biggest Psychedelic News Stories of the Week – June 23

The Biggest Psychedelic News Stories of the Week – June 23

,
New study brings hope to cancer patients struggling with depressive symptoms. Conflicts in Kentucky commission developing plan to fund research on the benefits of ibogaine to treat opioid addiction. Ayahuasca played a key role in finding Colombian children stranded in the Amazonian jungle.
Will the UK’s Ambitious Life Sciences Investment Power-Up the Psychedelic Sector?

Will the UK’s Ambitious Life Sciences Investment Power-Up the Psychedelic Sector?

,
As an emerging innovative sector addressing unmet mental health needs, psychedelic drug developers are poised to greatly benefit from the diverse initiatives offered within this package. 
World Psychedelics Day Marks 10 Days to the Beginning of Access to Psychedelic-Assisted Therapies in Australia

World Psychedelics Day Marks 10 Days to the Beginning of Access to Psychedelic-Assisted Therapies in Australia

,
June 20th marks World Psychedelic Day, and for Australians it has special significance psychedelic-assisted therapies in Australia this year.
Healing for All: Warriors of Consciousness Making Ketamine Therapy Accessible

Healing for All: Warriors of Consciousness Making Ketamine Therapy Accessible

Warriors of Consciousness helps individuals struggling with anxiety, PTSD and depression to get access to free ketamine therapy.
The Largest Phase 3 Trial on Psilocybin for Depression Has Kicked Off

The Largest Phase 3 Trial on Psilocybin for Depression Has Kicked Off

,
The largest Phase 3 clinical trial investigating the efficacy and tolerability of psilocybin for treatment-resistant depression (TRD) has finally begun.
psilocybin for depression

Single Dose of Psilocybin Yields Long-Term Depression Remission in Over 50% of Cancer Patients

,
A single 25mg dose of psilocybin paired with psychological support has resulted in 57% of patients.
MEAI: The Non-Hallucinogenic Psychedelic with an 'Enough Switch' for Addictions

MEAI: The Non-Hallucinogenic Psychedelic with an ‘Enough Switch’ for Addictions

,
MEAI seems to function like an “enough switch” in the brain, stopping all further desire for alcohol or cocaine and preventing overuse.
A "Trip-Less" Alternative? Non-Hallucinogenic LSD Analog Shows Promise for Treating Mood Disorders

A “Trip-Less” Alternative? Non-Hallucinogenic LSD Analog Shows Promise for Treating Mood Disorders

,
A non-hallucinogenic LSD analogue may be able to treat mood disorders and chronic stress without the hallucinations.

© 2023 Psychedelic Spotlight. | Owned and operated by PSYC Media Corporation, Inc. a US publicly traded company (OTCPink: PSYC) | All Rights Reserved.